Key Takeaways
- 14.9% mean weight loss at 68 weeks in STEP 1 (the landmark trial in adults without diabetes)
- 86.4% of participants lost at least 5% of body weight; 69.1% lost at least 10%
- People with type 2 diabetes lose less on average: 9.6% in the STEP 2 trial
- Weight loss is not permanent: most regain about two-thirds of lost weight within a year of stopping
- The SELECT trial showed a 20% reduction in major cardiovascular events, beyond just weight loss
- Real-world results are lower than trials: 3.7–5.1% at one year overall, 12.9% with full adherence
✓ FDA-Approved: Semaglutide is FDA-approved as Wegovy (2.4 mg weekly, for chronic weight management) and Ozempic (up to 2 mg weekly, for type 2 diabetes). The clinical data in this guide covers the 2.4 mg weight loss dose unless stated otherwise.
Semaglutide has become one of the most studied weight loss medications ever put into clinical trials. If you're researching it, whether through Wegovy, Ozempic, or a compounded version, the central question is: how much weight will you actually lose, and how quickly? This guide answers both using published trial data. For a full overview of the compound, see the semaglutide resource hub.
The short answer: in the best-designed clinical trials, people using 2.4 mg semaglutide weekly for 68 weeks lost an average of 14.9% of their body weight. That's about 33 lbs for someone starting at 220 lbs. But the average hides a wide range, and several factors, including whether you have diabetes, significantly affect where you land.
The trial evidence, a month-by-month timeline, real-world results, and the factors that determine your outcome are all covered below.
What Is Semaglutide and How Does It Cause Weight Loss?
Semaglutide is a GLP-1 receptor agonist, a synthetic version of a hormone your gut releases after eating. GLP-1 (glucagon-like peptide-1) normally acts for just a few minutes. Semaglutide has been chemically modified so it stays active for about seven days, which is why you only inject it once a week.
Three Ways Semaglutide Reduces Body Weight
1. Appetite suppression (brain)
Semaglutide crosses into the brain and activates GLP-1 receptors in the hypothalamus, the region that controls hunger. Most users report thinking about food less often, feeling satisfied on smaller portions, and finding previously tempting foods less appealing.
2. Slower gastric emptying (gut)
Food moves more slowly from your stomach into the intestine. This extends the feeling of fullness after eating and reduces post-meal blood sugar spikes. It also explains the nausea that many people experience, especially in the first few weeks at each new dose.
3. Improved insulin regulation (pancreas)
Semaglutide stimulates insulin release only when blood sugar is elevated. This glucose-dependent mechanism means it doesn't cause low blood sugar in most users. In people with type 2 diabetes, this also improves overall glycaemic control.
The result of all three effects is a sustained calorie deficit, driven by biology rather than willpower. Hunger signals are quieter, meals feel more filling, and you naturally eat less without feeling deprived. For a full explanation of the mechanism and the titration protocol that gets you to the effective dose, see the semaglutide dosing guide.
Clinical Evidence: What the STEP Trials Actually Show
The STEP (Semaglutide Treatment Effect in People with obesity) program is the core body of evidence behind semaglutide for weight loss. Four large randomised controlled trials ran from 2019 to 2021, involving nearly 5,000 participants across different populations.
STEP 1: The Landmark Trial
STEP 1 enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, without type 2 diabetes. All received lifestyle counselling alongside medication or placebo for 68 weeks.
14.9%
Mean weight loss (semaglutide)
2.4%
Mean weight loss (placebo)
15.3 kg
Absolute weight lost (33.7 lbs)
- ≥5% weight loss: 86.4% achieved this threshold (vs 31.5% on placebo)
- ≥10% weight loss: 69.1% achieved this (vs 12.0% on placebo)
- ≥15% weight loss: 50.5% achieved this (vs 4.9% on placebo)
- ≥20% weight loss: Approximately one-third of participants (exact figure varies between summary sources; the primary trial paper is the most reliable reference)
Source: Wilding JPH, et al. NEJM. 2021;384(11):989–1002. PMID 33567185
STEP 1 trial outcomes: 14.9% mean weight loss at 68 weeks across 1,961 participants — the landmark dataset for semaglutide weight management.
STEP 4: What Happens If You Keep Going?
STEP 4 asked a different question: what happens after 20 weeks of semaglutide use? Participants who had already lost a mean of 10.6% of their body weight were randomised to either continue semaglutide or switch to placebo.
- Continued semaglutide: Lost an additional 7.9% by week 68 (total ~17-18% from original baseline)
- Switched to placebo: Regained 6.9% within 48 weeks, recovering nearly all the weight they had lost during the run-in
- ≥20% total loss: 40% of those who continued semaglutide achieved this
STEP 4 established two things clearly: weight loss continues well beyond the initial months, and stopping the medication reverses most of the benefit within a year.
Source: Rubino DM, et al. JAMA. 2021;325(14):1414–1425. PMID 33755728
How Fast Does Semaglutide Work? Month-by-Month Timeline
Weight loss on semaglutide is not linear. It's fastest in the middle months as you reach higher doses, and it slows, though it doesn't stop, as you approach the endpoint of the clinical trials.
Weight Loss Timeline (Based on STEP 1 and STEP 4 Data)
| Timepoint | Mean Weight Loss | What's Happening |
|---|---|---|
| Month 1 (weeks 1–4) | ~2–4% | Dose at 0.25 mg; mild appetite reduction; some early water weight |
| Month 3 (week 12) | ~5–6% | Dose escalating through 0.5–1 mg; appetite suppression more consistent |
| Month 6 (week 24) | ~10–11% | Approaching or at 2.4 mg maintenance; fat loss well established |
| Month 12 (week 52) | ~14–16% | Sustained loss continuing; weight velocity slowing |
| Month 16 (week 68) | ~14.9% (STEP 1 endpoint) | Trial endpoint; loss still progressing in STEP 4 data |
| Year 4 | ~10.2% (sustained) | Long-term maintenance data; some regain vs peak, sustained vs placebo |
Timeline aggregated from STEP 1 (PMID 33567185), STEP 4 (PMID 33755728), and 4-year follow-up data (conference presentation, 2024). Individual results vary substantially.
Why the First Month Feels Slow
The standard titration starts at 0.25 mg, a sub-therapeutic dose designed purely for tolerance. At this level, you may notice subtle appetite changes, but the dose is not delivering the full therapeutic effect. Weight loss picks up meaningfully from month 3 onwards as you move through the 0.5 mg → 1 mg → 1.7 mg → 2.4 mg escalation.
Important: These timelines are averages. Individual variation is wide. Some people lose 3–4% in month 1; others lose less than 1%. Your trajectory at months 1–3 is a poor predictor of where you'll end up at month 12. Patience with the titration process matters.
How Much Weight Can You Lose on Semaglutide?
The 14.9% mean figure from STEP 1 is often cited, but it describes what happened to the average participant under controlled trial conditions with regular monitoring and lifestyle support. Real-world outcomes are meaningfully different.
RCT Results vs Real-World Outcomes
| Setting | Mean Weight Loss at 1 Year | Key Difference |
|---|---|---|
| STEP 1 (RCT) | ~14.9% at 68 weeks | Controlled; regular monitoring; lifestyle support; motivated participants |
| Real-world (full adherence) | ~12.9% at 1 year | Consistent dose-taking; closest to RCT conditions |
| Real-world (overall) | 3.7–5.1% at 1 year | Variable adherence; dose gaps; no monitoring support |
Real-world data from: JAMA Network Open. 2024. 37% of real-world participants achieved ≥10% loss at one year.
Factors That Affect Your Individual Result
Several variables shift where you land relative to the clinical average:
- Dose reached: Participants who reached and maintained 2.4 mg drove most of the average. If you can only tolerate 1 mg due to side effects, expect proportionally less.
- Consistency: Missing doses significantly reduces efficacy. The real-world data gap (5% vs 14.9%) is largely explained by variable adherence.
- Diabetes status: People with type 2 diabetes lose less (see the next section).
- Baseline metabolic health: Insulin resistance, thyroid conditions, and PCOS can blunt response.
- Diet and physical activity: All STEP trials included lifestyle counselling. Results without it are likely lower.
- Concurrent medications: Antipsychotics, corticosteroids, and some antidepressants can partially offset weight loss.
- Sleep and stress: Poor sleep elevates cortisol, which works against fat loss.
Use the semaglutide dose calculator to visualise your dosing schedule and how drug levels build up over your titration period.
Plan Your Semaglutide Journey
See how drug levels build up over your titration, calculate your syringe volumes, and get AI-assisted guidance on your protocol.
Does Diabetes Affect Your Results? STEP 2 vs STEP 1
This is one of the most clinically important nuances about semaglutide weight loss, and it's often glossed over in mainstream coverage. People with type 2 diabetes consistently lose less weight than people without it, even at the same dose and duration.
STEP 2: Type 2 Diabetes Population
STEP 2 enrolled 1,210 adults with type 2 diabetes and overweight or obesity for 68 weeks, the same duration as STEP 1.
- 2.4 mg semaglutide: 9.6% mean weight loss (vs 3.4% placebo)
- 1.0 mg semaglutide: 7.0% mean weight loss
- HbA1c reduction: 1.6% with 2.4 mg, a significant glycaemic improvement
Source: Davies MJ, et al. Lancet. 2021;397(10278):971–984. PubMed PMID 33567187
Why Does Diabetes Reduce Weight Loss?
This is partly a biological difference. People with type 2 diabetes often have higher insulin levels (hyperinsulinaemia), and insulin promotes fat storage. Medications used to manage diabetes can also counteract weight loss, particularly insulin itself and sulfonylureas. The physiological environment simply resists fat loss more strongly in this population.
| Trial | Population | 2.4 mg Weight Loss |
|---|---|---|
| STEP 1 | No diabetes | 14.9% |
| STEP 2 | Type 2 diabetes | 9.6% |
If you have type 2 diabetes, 9–10% weight loss at 68 weeks is the realistic target on semaglutide 2.4 mg. That's still clinically meaningful, sufficient to improve blood sugar, blood pressure, and cardiovascular risk, but roughly 35% less than the non-diabetes result.
What Happens When You Stop Taking Semaglutide?
This is the part most people don't hear about before they start. The weight loss from semaglutide is tied to the drug being active in your body. When you stop, the biological mechanisms that were suppressing your appetite return to their pre-medication state, and the weight follows.
STEP 1 Extension: One Year After Stopping
The STEP 1 extension study followed participants after they stopped semaglutide at week 68. By week 120 (approximately one year post-discontinuation):
- Mean weight regain: 11.6% of body weight, approximately two-thirds of all weight previously lost
- Net weight loss from original baseline: only 5.6% at week 120
- Cardiometabolic improvements (blood pressure, cholesterol, blood sugar) largely reversed in parallel
Source: Wilding JPH, et al. Diabetes Obes Metab. 2022;24(8):1553–1564. PMID 35441470
Why Regain Happens (and What It Means)
Obesity is now understood as a chronic disease, one driven by biology rather than behaviour. Your body has set-point mechanisms that defend a higher weight: hunger hormones increase, metabolism slows, and reward pathways pull you back towards old eating patterns. Semaglutide suppresses these mechanisms while you take it. When you stop, they return.
This isn't a failure of willpower. It's the same reason people with hypertension need to keep taking blood pressure medication long-term. For many people, semaglutide is a long-term treatment, not a course.
Note on 4-year data: A 2024 conference presentation reported a sustained mean loss of 10.2% at four years, compared to 1.5% for placebo, suggesting meaningful long-term benefit for continuous users. This data comes from a conference/abstract presentation rather than a fully peer-reviewed publication at time of writing. Treat it as preliminary.
SELECT Trial: Cardiovascular Benefits Beyond Weight Loss
In 2023, semaglutide became notable for a different reason: the SELECT trial showed it reduced the risk of serious heart events in people with obesity who already had cardiovascular disease.
SELECT Trial Results
SELECT enrolled 17,604 adults with established cardiovascular disease, BMI ≥27, and no diabetes. Average follow-up: 39.8 months.
- Primary MACE reduction: 6.5% (semaglutide) vs 8.0% (placebo), a 20% relative risk reduction (HR 0.80, 95% CI 0.72–0.90, P<0.001)
- MACE = major adverse cardiovascular events: heart attack, stroke, or cardiovascular death
- Weight loss at 104 weeks: ~9.4% (semaglutide) vs ~0.9% (placebo)
- Cardioprotective effect appeared partly independent of the weight loss itself; GLP-1 receptors in the heart may play a direct role
Source: Lincoff AM, et al. NEJM. 2023;389(24):2221–2232. PMID 37952131
Based on this, the FDA updated the Wegovy prescribing label to include cardiovascular risk reduction as an indication in eligible patients. For people with obesity and cardiovascular disease, semaglutide does more than reduce the number on the scale.
Semaglutide vs Tirzepatide: Which Causes More Weight Loss?
If you're researching semaglutide, you've probably also come across tirzepatide (Mounjaro, Zepbound). The data consistently shows tirzepatide produces greater weight loss, but context matters.
What the Head-to-Head Data Shows
| Drug | Mechanism | Peak Trial Weight Loss | Trial Duration |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | 14.9% (STEP 1) | 68 weeks |
| Tirzepatide (Zepbound) | GLP-1 + GIP dual agonist | 20.9% (SURMOUNT-1, 15 mg) | 72 weeks |
A head-to-head trial (SURPASS-2) directly compared the two in type 2 diabetes patients. Tirzepatide at 15 mg produced 5.5 kg greater weight loss than semaglutide 1 mg at 40 weeks. However, the semaglutide dose in that trial was 1 mg (the diabetes dose), not the 2.4 mg weight loss dose. A true head-to-head in the weight loss indication has not yet been published.
The practical implication: tirzepatide appears to produce meaningfully more weight loss, particularly at higher doses. Semaglutide remains effective and has a longer safety track record. For a full comparison, see our compounded semaglutide guide which also covers cost and sourcing differences.
Source: Frías JP, et al. NEJM. 2021;385(6):503–515. PMID 34170647
Who Qualifies for Semaglutide for Weight Loss?
The FDA-approved criteria for Wegovy (semaglutide 2.4 mg) are based on body mass index (BMI) and the presence of weight-related health conditions.
FDA Eligibility Criteria (Wegovy)
- BMI ≥30 (obesity), regardless of other conditions
- BMI ≥27 with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease
- Adults only (FDA approval; paediatric approval for adolescents ≥12 years came separately)
- Contraindications: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), or prior serious allergic reaction to semaglutide
Source: Wegovy FDA Prescribing Information, 2021
Compounded Semaglutide and Access
During brand-name shortages (2022–2024), many people accessed semaglutide through compounding pharmacies. Compounded semaglutide is not FDA-approved: it is prepared by licensed compounding pharmacies and falls outside standard FDA safety review for the finished product.
⚠️ FDA Warning: The FDA has expressed concerns about unapproved GLP-1 drugs used for weight loss, including variable purity and concentration in compounded versions. If using compounded semaglutide, obtain it from a licensed 503A or 503B pharmacy and request a Certificate of Analysis (CoA). FDA guidance
GLP3 Planner's tools work with both brand-name and compounded formulations. Use the semaglutide calculator to map your exact dosing protocol regardless of source.
Track Your Progress With GLP3 Planner
Plot your dosing schedule, calculate vial volumes, and get answers about your semaglutide protocol.
How to Get the Best Results on Semaglutide
The 14.9% STEP 1 result wasn't achieved by medication alone. All trial participants received structured lifestyle counselling. The clinical data tells us the medication works; the gap between RCT and real-world results tells us that how you use it matters significantly.
1. Follow the Titration: Don't Rush It
The standard 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg escalation over 16–20 weeks exists for good reason. Skipping ahead leads to higher rates of nausea, vomiting, and discontinuation. If you're losing weight steadily at 1 mg or 1.7 mg with good tolerability, there's no requirement to force your way to 2.4 mg. See the full semaglutide dosing guide for protocol details.
2. Protect Muscle Mass
Rapid weight loss, from any cause, includes some lean mass loss alongside fat. Resistance training and adequate protein intake (aim for 1.2–1.6 g per kg of body weight daily) significantly reduce the proportion lost as muscle. Don't skip this step.
3. Take Dose Consistency Seriously
Semaglutide has a ~7-day half-life. Missing a dose once in 5 days won't devastate your levels; take it as soon as you remember. Missing more than 5 days means skipping and resuming your regular schedule. Repeated gaps compound into meaningfully lower average drug concentrations, which explains much of the real-world adherence gap.
The standard semaglutide titration: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16–20 weeks. Dose consistency at each step drives results.
4. Track Your Weight Objectively
Weight fluctuates daily by 1–3 kg due to water, food volume, and hormones. Looking only at daily readings creates false patterns. Track weekly averages, or use a trend-based tracking app. The GLP3 Planner biometric tracking tool (built into the dosing plotter) lets you log weight alongside your dose history for accurate trend visibility.
Does Diet and Exercise Matter on Semaglutide?
A common misconception: that semaglutide does the work and diet doesn't matter. This isn't what the trial data shows. Lifestyle intervention was included in every STEP trial arm, including placebo, and the placebo group still lost 2.4% on lifestyle alone.
More practically: semaglutide reduces hunger, which makes eating better dramatically easier. The medication lowers the effort required to eat in a calorie deficit. But if you continue eating ultra-processed foods, skip protein, and remain sedentary, you'll leave a meaningful portion of your potential results unrealised.
Practical priorities: Protein first at each meal (25–30 g per meal), limit liquid calories (alcohol, sugary drinks), eat until satisfied not stuffed (semaglutide changes your satiety signals, so listen to them), and add resistance training 2–3 times per week to protect muscle. These aren't optional extras; they're what separate 10% from 20% outcomes.
Is Semaglutide Safe for Weight Loss?
Semaglutide's safety profile is well-established. Wegovy for weight management was approved in June 2021, and semaglutide in the Ozempic formulation has been in use for type 2 diabetes since 2017. The compound has been observed in large populations across multiple trials and years of post-market surveillance.
Common Side Effects
Most side effects are gastrointestinal and occur predominantly during dose escalation. In STEP 1, nausea affected 44% of participants (vs 17% placebo), but most cases were mild-to-moderate and resolved with adaptation. For a full breakdown by dose and category, see the semaglutide side effects guide.
Serious Risks (Rare but Important)
Contact a healthcare provider immediately if you experience:
- Severe abdominal pain: potential pancreatitis signal
- Persistent vomiting causing dehydration
- Signs of allergic reaction: swelling of face or throat, difficulty breathing
- Gallbladder pain: GLP-1 medications are associated with gallstone formation
- Rapid heartbeat at rest: semaglutide can increase resting heart rate by ~4 bpm on average
Long-Term Safety
The SELECT cardiovascular outcomes trial followed 17,604 participants for nearly four years and found no increased risk of serious adverse events; in fact, the treatment group had fewer cardiovascular events. This is currently the longest and largest safety dataset for semaglutide 2.4 mg. Longer-term data (10+ years) does not yet exist.
Frequently Asked Questions
How much weight can you lose on semaglutide?
In the STEP 1 clinical trial, participants without type 2 diabetes lost a mean of 14.9% of body weight over 68 weeks, about 15.3 kg (33.7 lbs) on average. Results vary significantly: 86.4% lost at least 5%, and roughly one-third lost 20% or more. People with type 2 diabetes lose less on average, around 9.6% (STEP 2 trial). Real-world outcomes with variable adherence tend to fall between 4–13% at one year. Visit our semaglutide hub for more context.
How fast do you lose weight on semaglutide?
Appetite changes can appear within the first week, even at the 0.25 mg starting dose. Measurable weight loss (2–4%) typically appears by month 1. By month 3, most people have lost around 5–6%. By month 6, 10–11%. Weight loss velocity is fastest between months 3 and 6 as you reach therapeutic doses, then slows but continues through month 16 and beyond. The first month on the 0.25 mg starting dose is the slowest period.
Does semaglutide weight loss last?
Weight loss is maintained only while you continue taking semaglutide. The STEP 1 extension study found that participants regained a mean of 11.6% of body weight (about two-thirds of all weight previously lost) within one year of stopping. Long-term data at four years shows sustained loss of approximately 10.2% for continuous users. For most people, semaglutide is a long-term treatment rather than a short course.
What happens when you stop taking semaglutide?
Stopping semaglutide reverses the biological effects that drove weight loss: appetite returns, gastric emptying speeds up, and hunger hormones resume their pre-medication patterns. Most people begin regaining weight within weeks of discontinuation. By one year post-stop, the average person has regained approximately two-thirds of previously lost weight, with metabolic markers (blood pressure, cholesterol) also returning toward baseline. This is why many providers recommend long-term use for sustained benefit.
Is semaglutide FDA-approved for weight loss?
Yes. Semaglutide 2.4 mg (Wegovy) was FDA-approved in June 2021 for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related condition. In 2023, Wegovy's label was updated to include cardiovascular risk reduction in eligible patients following the SELECT trial. Ozempic (up to 2 mg) is approved for type 2 diabetes, not weight management specifically, though it is frequently prescribed off-label for weight loss.
How does semaglutide compare to tirzepatide for weight loss?
Tirzepatide (Zepbound/Mounjaro) produces greater weight loss than semaglutide in clinical trial data, approximately 20.9% at 72 weeks (SURMOUNT-1) compared to semaglutide's 14.9% at 68 weeks (STEP 1). These are separate trials with different populations, not a direct head-to-head. Tirzepatide's dual GLP-1/GIP mechanism appears to offer incremental benefit. Semaglutide has a longer post-approval safety record and established cardiovascular outcomes data. Both are effective; the choice depends on individual response, tolerability, and access.
Does semaglutide work better with diet and exercise?
Yes. All STEP trials included structured lifestyle counselling alongside medication. The real-world data showing 3.7–5.1% average weight loss at one year (vs 14.9% in trials) likely reflects both variable adherence to medication and the absence of the structured dietary and exercise support that trial participants received. Protein intake, consistent dosing, and resistance training are the levers most supported by evidence for maximising semaglutide outcomes.
Can compounded semaglutide produce the same weight loss results?
Clinical trial data exists only for pharmaceutical-grade semaglutide (Wegovy/Ozempic). Compounded semaglutide theoretically delivers the same active molecule, but purity, concentration, and bioavailability can vary between compounding pharmacies. Real-world clinic data shows meaningful weight loss with compounded versions, but this cannot be directly compared to RCT results due to selection bias and variable quality. If using compounded semaglutide, request a Certificate of Analysis from a licensed 503A or 503B pharmacy and follow the standard Wegovy titration protocol.
Is semaglutide the same as Ozempic and Wegovy?
Yes, the active molecule is the same. Ozempic and Wegovy are both brand-name formulations of semaglutide, made by Novo Nordisk. The key differences are the approved dose (Ozempic up to 2 mg; Wegovy up to 7.2 mg, with 2.4 mg the recommended maintenance dose), the approved indication (diabetes vs weight management), and the pen delivery system. Rybelsus is an oral tablet formulation of semaglutide for type 2 diabetes at lower doses. Compounded semaglutide aims to replicate the same molecule from a different manufacturing source.
Ready to Map Your Protocol?
Use our free tools to visualise your dosing schedule, calculate reconstitution volumes, and get guidance tailored to your situation.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. PubMed PMID 33567185
- Davies MJ, Bergenstal R, Bode B, et al. (STEP 2 Study Group). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971–984. PubMed PMID 33567187
- Rubino DM, Greenway FL, Khalid U, et al. (STEP 4). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414–1425. PubMed PMID 33755728
- Wilding JPH, Batterham RL, Davies M, et al. (STEP 1 Extension). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553–1564. PubMed PMID 35441470
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT trial). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. PubMed PMID 37952131
- Frías JP, Davies MJ, Rosenstock J, et al. (SURPASS-2). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. PubMed PMID 34170647
- Wilding JPH, et al. 4-year sustained weight loss with semaglutide 2.4 mg in adults with obesity. Presented at ObesityWeek/EASO 2024. Obesity. 2024. Note: conference presentation data; verify full peer-reviewed publication before citing as primary source.
- Real-world cohort analysis. Weight Loss Outcomes with Semaglutide in Real-World Settings. JAMA Network Open. 2024. doi: jamanetwork.com/journals/jamanetworkopen/fullarticle/2823644
- FDA. Wegovy (semaglutide) 2.4 mg Prescribing Information. FDA.gov. 2021. accessdata.fda.gov
- FDA. FDA's Concerns About Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
⚕️ Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Semaglutide is a prescription medication approved for specific indications; it should only be used under the supervision of a qualified healthcare provider. Clinical trial data represents averages across study populations; individual results vary significantly based on dose, adherence, diabetes status, lifestyle factors, and genetics. Weight loss results from compounded semaglutide have not been evaluated in controlled trials. Always consult your doctor before starting, stopping, or changing any medication regimen. The information provided here should not replace professional medical advice, diagnosis, or treatment.
Related Articles
Semaglutide Resource Hub
Everything about semaglutide: dosing, side effects, reconstitution, and tools.
Complete Semaglutide Dosing Guide
Titration schedules, pharmacokinetics, missed dose protocols, and compounded formulation details.
Semaglutide Side Effects Guide
Common GI symptoms, dose-by-dose data, and management strategies from STEP trial evidence.
Semaglutide Microdosing Guide
Split-dose strategies for people who struggle with the standard weekly schedule.
Compounded Semaglutide Guide
Sourcing, quality considerations, pricing, and safety for compounded peptide users.
Semaglutide Reconstitution Guide
Step-by-step reconstitution with BAC water, vial prep, and volume calculations.